778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectabl... by Gino K In, James Larkin, Yazan Samhouri, Marcus Butler, Victoria Atkinson, Jeffrey Chou, Juan Martin-Liberal, Patrick Terheyden, Sajeve Thomas, Wen Shi, Xiao Wu, Andrew S Poklepovic, Young Hong, Giri Sulur, Friedrich Graf Finckenstein, John B Haanen, Andrew JS Furness, Philip Lammers, Ryan H Nguyen, Idit Peretz